Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer
← catalyst calendarNCT06555796 · readout in 50 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
50actual
Sites
11
Countries
Australia, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-09-23 | actual | When the study began enrolling |
| Primary completion | 2026-10-08 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-12-02 | estimated | The whole study's end, after follow-up |
| First posted | 2024-08-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Prostate Cancer
- High-risk Biochemical Recurrence
- High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer
- Non-metastatic Castration-sensitive Prostate Cancer
Intervention
- Drug: Xaluritamig — also filed as AMG 509
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
measured Up to approximately 2 years
Number of Participants Experiencing Treatment-related Adverse Events (TRAEs)
measured Up to approximately 2 years
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed